The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While https://haseebnzzs440807.wikicorrespondence.com/6038657/glp_3_retatrutide_a_comparative_analysis